comparemela.com

Latest Breaking News On - Karolin riehle - Page 4 : comparemela.com

Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: Joint Venture Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the.

Karolin riehleEckert zieglerQi kang medical technology changzhou co ltdDongcheng pharma

EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes - adhoc - Börsennachrichten

EQSAdhoc Eckert & Ziegler Strahlen und Medizintechnik AG Key word Joint Venture Eckert & Ziegler Establishes GermanChinese Joint Venture with DC Pharma for the Production of Radioisotopes 14N

Karolin riehleEckert zieglerQi kang medical technology changzhou co ltdDongcheng pharma

Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): ContractEckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials 23.10.2023 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin, Germany and Shanghai, China – 23 Octob.

San diegoUnited statesJutta ludwigEckert zieglerAlex qiaoEckert ziegler strahlenKarolin riehleEckert ziegler to supply ablaze pharmaceuticalsRayzebio incBund centerAblaze pharmaceuticals shanghai co ltdAblaze pharmaceuticalsDistribution servicesSupply ablaze pharmaceuticalsClinical trialsExecutive board

Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Compe

EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company DecisionEckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG 20.10.2023 / 15:40 CET/CESTThe issuer is solely responsible for the cont.

Andreas eckertKarolin riehleEckert ziegler strahlenHarald hasselmannEckert zieglerStrategic company decisionDistribution servicesSupervisory board decideInvestment prioritiesCore competenciesExecutive boardSupervisory boardMyelo therapeutics gmbhCorporate newsRegulatory announcements

EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets - adhoc - Börsennachrichten

EQSAdhoc Eckert & Ziegler Strahlen und Medizintechnik AG Key word Strategic Company Decision Eckert & Ziegler Focuses on Core Competence and Prepares SplitOff of Clinical Assets 20Oct2023 151

Karolin riehleEckert zieglerSupervisory boardExecutive boardMyelo therapeutics

vimarsana © 2020. All Rights Reserved.